Alexandre F Marques

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2115347/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model. PLoS Neglected Tropical Diseases, 2021, 15, e0009613.	3.0	7
2	C57BL/6 α-1,3-Galactosyltransferase Knockout Mouse as an Animal Model for Experimental Chagas Disease. ACS Infectious Diseases, 2020, 6, 1807-1815.	3.8	7
3	Preliminary assessment of anti-α-Gal IgG and IgM levels in patients with patent Plasmodium vivax infection. Memorias Do Instituto Oswaldo Cruz, 2019, 114, e190145.	1.6	3
4	A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease. Npj Vaccines, 2019, 4, 13.	6.0	40
5	An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy. Frontiers in Cellular and Infection Microbiology, 2019, 9, 427.	3.9	26
6	Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2018, 18, 419-430.	9.1	214
7	Role of antimicrobial stewardship programmes in children: a systematic review. Journal of Hospital Infection, 2018, 99, 117-123.	2.9	66
8	Activation of Human CD11b+ B1 B-Cells by Trypanosoma cruzi-Derived Proteins Is Associated With Protective Immune Response in Human Chagas Disease. Frontiers in Immunology, 2018, 9, 3015.	4.8	20
9	Probing forÂTrypanosoma cruzi Cell SurfaceÂGlycobiomarkers for the Diagnosis and Follow-Up of Chemotherapy of Chagas Disease. , 2018, , 195-211.		4
10	Specific activation of CD4–CD8– double-negative T cells by <i>Trypanosoma cruzi</i> -derived glycolipids induces a proinflammatory profile associated with cardiomyopathy in Chagas patients. Clinical and Experimental Immunology, 2017, 190, 122-132.	2.6	17
11	Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against <i>Leishmania</i> Infection. ACS Central Science, 2017, 3, 1026-1031.	11.3	67
12	Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease. ACS Infectious Diseases, 2016, 2, 917-922.	3.8	17
13	Refolding, purification, and preliminary structural characterization of the DNA-binding domain of the quorum sensing receptor RhlR from Pseudomonas aeruginosa. Protein Expression and Purification, 2016, 121, 31-40.	1.3	3
14	Amblyomma sculptum tick saliva: α-Gal identification, antibody response and possible association with red meat allergy in Brazil. International Journal for Parasitology, 2016, 46, 213-220.	3.1	93
15	Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. PLoS Neglected Tropical Diseases, 2016, 10, e0004269.	3.0	34
16	Allosteric regulation of the Plasmodium falciparum cysteine protease falcipain-2 by heme. Archives of Biochemistry and Biophysics, 2015, 573, 92-99.	3.0	13
17	Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease. Glycobiology, 2015, 26, cwv081.	2.5	27
18	Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2014, 8, e3077.	3.0	37

#	Article	IF	CITATIONS
19	A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine, 2014, 32, 3525-3532.	3.8	57
20	Potential use of synthetic α-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease. Organic and Biomolecular Chemistry, 2013, 11, 5579.	2.8	37
21	Proteomic Analysis of <i>Trypanosoma cruzi</i> Secretome: Characterization of Two Populations of Extracellular Vesicles and Soluble Proteins. Journal of Proteome Research, 2013, 12, 883-897.	3.7	235
22	Falcipain-2 inhibition by suramin and suramin analogues. Bioorganic and Medicinal Chemistry, 2013, 21, 3667-3673.	3.0	24
23	Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 928-931.	1.6	19
24	Therapeutic DNA Vaccine Encoding Peptide P10 against Experimental Paracoccidioidomycosis. PLoS Neglected Tropical Diseases, 2012, 6, e1519.	3.0	44
25	Intraspecies Variation in Trypanosoma cruzi GPI-Mucins: Biological Activities and Differential Expression of α-Galactosyl Residues. American Journal of Tropical Medicine and Hygiene, 2012, 87, 87-96.	1.4	34
26	Improved Proteomic Approach for the Discovery of Potential Vaccine Targets in <i>Trypanosoma cruzi</i> . Journal of Proteome Research, 2012, 11, 237-246.	3.7	49
27	Poly(lactic acidâ€glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis. British Journal of Pharmacology, 2010, 159, 1126-1132.	5.4	46
28	Resistance of melanized yeast cells of Paracoccidioides brasiliensis to antimicrobial oxidants and inhibition of phagocytosis using carbohydrates and monoclonal antibody to CD18. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 644-648.	1.6	38
29	Enhanced prion protein stability coupled to DNA recognition and milieu acidification. Biophysical Chemistry, 2009, 141, 135-139.	2.8	10
30	Additive effect of P10 immunization and chemotherapy in anergic mice challenged intratracheally with virulent yeasts of Paracoccidioides brasiliensis. Microbes and Infection, 2008, 10, 1251-1258.	1.9	45
31	Experimental paracoccidioidomycosis: alternative therapy with ajoene, compound from <i>Allium sativum</i> , associated with sulfamethoxazole/trimethoprim. Medical Mycology, 2008, 46, 113-118.	0.7	27
32	In Vitro Activity of the Antifungal Plant Defensin RsAFP2 against <i>Candida</i> Isolates and Its In Vivo Efficacy in Prophylactic Murine Models of Candidiasis. Antimicrobial Agents and Chemotherapy, 2008, 52, 4522-4525.	3.2	79
33	The Monoclonal Antibody against the Major Diagnostic Antigen of <i>Paracoccidioides brasiliensis</i> Mediates Immune Protection in Infected BALB/c Mice Challenged Intratracheally with the Fungus. Infection and Immunity, 2008, 76, 3321-3328.	2.2	60
34	Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: effects on phagocytosis, intracellular resistance and drug susceptibility. Microbes and Infection, 2006, 8, 197-205.	1.9	102
35	Peptide Immunization as an Adjuvant to Chemotherapy in Mice Challenged Intratracheally with Virulent Yeast Cells of Paracoccidioides brasiliensis. Antimicrobial Agents and Chemotherapy, 2006, 50, 2814-2819.	3.2	68
36	Detection of Immune Complexes Is Not Independent of Detection of Antibodies in Lyme Disease Patients and Does Not Confirm Active Infection with Borrelia burgdorferi. Vaccine Journal, 2005, 12, 1036-1040.	3.1	19

#	Article	IF	CITATIONS
37	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. Journal of Autoimmunity, 2001, 16, 187-192.	6.5	61
38	Purification of extracellular and intracellular amastigotes of Trypanosoma cruzi from mammalian host-infected cells. Protocol Exchange, 0, , .	0.3	8